2025
Deucravacitinib in Psoriasis Patients with a History of Malignancy: Follow-up after 4 Years of Deucravacitinib Treatment in the POETYK PSO Program
Lebwohl M, Korman N, Gooderham M, Gottlieb A, Foley P, Eyerich K, Romanelli M, Strober B, Morita A, Li L, Daamen C, Vaile J, Badaka R, Alió A, Puig L. Deucravacitinib in Psoriasis Patients with a History of Malignancy: Follow-up after 4 Years of Deucravacitinib Treatment in the POETYK PSO Program. SKIN The Journal Of Cutaneous Medicine 2025, 9: s538. DOI: 10.25251/skin.10.supp.538.Peer-Reviewed Original ResearchHistory of malignancyOccurrence of malignancyPsoriasis patientsFollow-upDuration of follow-upBaseline patient demographicsTyrosine kinase 2 inhibitorLong-term extensionYear prior to enrollmentTreatment discontinuationClinical characteristicsPatient demographicsPatient withdrawalAdverse eventsDeucravacitinibMalignancyPatient populationMalignant eventsPatientsPsoriasisPooled populationNMSCTrialsBaselineTreatment
2022
Quality of Life Improvements in Women with Uterine Fibroids: Results of Two Phase 3 Trials with Linzagolix [A107]
Al-Hendy A, Bradley L, Taylor H, Catherino W, Humberstone A, Garner E. Quality of Life Improvements in Women with Uterine Fibroids: Results of Two Phase 3 Trials with Linzagolix [A107]. Obstetrics And Gynecology 2022, 139: 31s-31s. DOI: 10.1097/01.aog.0000826748.26150.66.Peer-Reviewed Original ResearchPhase 3 trialUterine fibroidsPlacebo-controlled phase 3 trialTreatment of UFsFibroid-related symptomsHealth-related qualifyOral GnRH antagonistHealth-related qualityEnd of treatmentLong-term impairmentSubstantial beneficial effectPlacebo groupGnRH antagonistLife QuestionnaireSexual functionWeek 64Mean changeFrequent causeTreatment terminationEstradiol suppressionTreatment groupsLinzagolixPooled populationBeneficial effectsTotal score
2019
Epigenetic Associations With Estimated Glomerular Filtration Rate Among Men With Human Immunodeficiency Virus Infection
Chen J, Huang Y, Hui Q, Mathur R, Gwinn M, So-Armah K, Freiberg MS, Justice AC, Xu K, Marconi VC, Sun YV. Epigenetic Associations With Estimated Glomerular Filtration Rate Among Men With Human Immunodeficiency Virus Infection. Clinical Infectious Diseases 2019, 70: 667-673. PMID: 30893429, PMCID: PMC7319269, DOI: 10.1093/cid/ciz240.Peer-Reviewed Original ResearchConceptsChronic kidney diseaseHuman immunodeficiency virus (HIV) infectionImmunodeficiency virus infectionGlomerular filtration rateKidney functionFiltration rateVirus infectionVeterans Aging Cohort StudyPeripheral blood mononuclear cellsAging Cohort StudyHIV-positive participantsBlood mononuclear cellsMechanisms of HIVCKD riskCohort studyKidney diseaseMononuclear cellsHigh riskHIVPooled populationEGFREpigenetic associationsSignificant CpG sitesGuanine dinucleotide sitesPotential epigenetic mechanisms
2018
Intra-thoracic Impedance and the Onset of Atrial and Ventricular Tachyarrhythmias: A Meta-analysis
Abubakar H, Osman M, Akintoye E, Subahi A, Osman K, Abidov A. Intra-thoracic Impedance and the Onset of Atrial and Ventricular Tachyarrhythmias: A Meta-analysis. International Journal Of Cardiology 2018, 258: 144-150. PMID: 29544921, DOI: 10.1016/j.ijcard.2017.12.092.Peer-Reviewed Original ResearchConceptsAT/AFVT/VFOptiVol fluid indexOdds ratioImplantable cardioverter-defibrillator devicesSignificant risk factorsFluid index threshold crossingCardioverter-defibrillator devicesLarger pooled populationFluid overloadVentricular tachyarrhythmiasArrhythmic eventsRisk factorsFluid indexMeta-analysisPatientsICD devicesPooled populationEffect estimatesConfidence intervalsOnsetPooled samplesVFAssociationAF
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply